Ryma Matthias, Scheibel Thomas
Department of Biomaterials, University of Bayreuth, Prof.-Rüdiger-Bormann-Str. 1, 95447 Bayreuth, Germany.
Chair for Functional Materials in Medicine and Dentistry at the Institute for Functional Materials and Biofabrication, University of Würzburg and Bavarian Polymer Institute, Pleicherwall 2, 97070 Würzburg, Germany.
Langmuir. 2025 Aug 12;41(31):20433-20442. doi: 10.1021/acs.langmuir.5c01463. Epub 2025 Aug 3.
Biofabrication holds immense potential for advancing tissue models used in in vitro testing. Despite significant technological advancements, there are currently no commercially viable biofabricated in vitro models, e.g., for drug testing. In contrast, established systems like organ-on-a-chip (OoC) and transwell-based tissue models are widely used, providing reliable solutions for drug testing but with limitations in tissue size, complexity, and customizability. Despite its potential to create complex tissue architectures, biofabrication has yet to become commercially viable. This perspective explores the key technological challenges limiting biofabrication's full potential in commercial in vitro testing and outlines how advancements in matrix compatibility, interface stability, and end-user usability can help overcome these barriers to unlock its transformative impact.
生物制造在推进体外测试中使用的组织模型方面具有巨大潜力。尽管取得了重大技术进步，但目前尚无商业上可行的生物制造体外模型，例如用于药物测试的模型。相比之下，诸如芯片器官（OoC）和基于Transwell的组织模型等成熟系统被广泛使用，为药物测试提供了可靠的解决方案，但在组织大小、复杂性和可定制性方面存在局限性。尽管生物制造有潜力创建复杂的组织结构，但尚未实现商业可行性。本文探讨了限制生物制造在商业体外测试中充分发挥潜力的关键技术挑战，并概述了基质兼容性、界面稳定性和终端用户可用性方面的进步如何有助于克服这些障碍，以释放其变革性影响。
